Efficacy of sacituzumab govitecan in a patient with heavily pretreated metastatic triple-negative breast cancer – a case study

Bulgarian Medical Journal, 2025, 19(3), 63-67.

V. Minchev¹, N. Chilingirova²

¹ Ward of Medical Oncology, UMHAT Sofiamed – Sofia
² Ward of Medical Oncology, “Heart and Brain” Hospital – Pleven

Abstract. Triple-negative breast cancer is associated with a poor prognosis owing to a lack of actionable molecular features, which has historically limited treatment options to chemotherapy. Recent advances in targeted approaches to the treatment of cancer, such as through antibody-drug conjugates (ADCs), hold promise for improving the outcomes of patients with metastatic TNBC. Sacituzumab govitecan, an ADC composed of an anti-Trop2 antibody and irinotecan active metabolite SN-38, has been approved for patients with unresectable locally-advanced or metastatic TNBC, who have already received at least two prior systemic therapies. Herein, we report a case of a 43-year-old patient with metastatic TNBC, who had undergone multiple lines of chemotherapy as well as targeted treatment with a PARP inhibitor. Having progressed on all prior lines, the patient received sacituzumab govitecan, which resulted in a considerable reduction of lesion sizes and partial remission. The current work adds to a growing body of case reports and real-world studies on the safety and efficacy of sacituzumab govitecan in metastatic TNBC.

Key words: triple-negative breast cancer, antibody-drug conjugate, case report, sacituzumab govitecan, PARP inhibitor, metastatic disease

Address for correspondence: Velko Minchev, MD, e-mail: v_minchev@abv.bg